Literature DB >> 28198170

Antibacterial effect of sevoflurane and isoflurane.

M Martínez-Serrano1, M Gerónimo-Pardo, A Martínez-Monsalve, M D Crespo-Sánchez.   

Abstract

OBJECTIVE: Multidrug resistant bacteria are increasing worldwide and therapeutic options are limited. Some anaesthetics have shown antibacterial activity before. In this study, we have investigated the antibacterial effect of the halogenated anaesthetic agents sevoflurane and isoflurane against a range of resistant pathogens.
METHODS: Two experiments were conducted. In the first, bacterial suspensions of both ATCC and resistant strains of Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa were exposed to liquid sevoflurane and isoflurane during 15, 30 and 60 minutes. In the second experiment clinical resistant strains of E. coli, Klebsiella pneumoniae, Enterobacter cloacae, P. aeruginosa, Acinetobacter baumannii, S. aureus, and Enterococcus faecium were studied. Previously inoculated agar plates were irrigated with the halogenated anaesthetic agents and these were left to evaporate before the plates were incubated. In both experiments colony forming units were counted in resultant plates.
RESULTS: In the first experiment, isoflurane showed faster and higher antimicrobial effect than sevoflurane against all the strains studied. Gram-negative organisms were more susceptible. In the second experiment, E. faecium was found to be resistant to both halogenated agents; only isoflurane showed statistically significant activity against the rest of the strains studied.
CONCLUSIONS: Both halogenated agents, but particularly isoflurane, showed in vitro antibacterial activity against pathogens resistant to conventional antibiotics. Further investigation is required to determine whether or not they also exhibit this property in vivo. This might then allow these agents to be considered as rescue treatment against multidrug resistant pathogens, including a topical use in infected wounds.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28198170

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  6 in total

1.  Topical sevoflurane for chronic venous ulcers infected by multi-drug-resistant organisms.

Authors:  Adrián Imbernón-Moya; Francisco Javier Ortiz-de Frutos; Mónica Sanjuan-Alvarez; Isabel Portero-Sanchez; Raúl Merinero-Palomares; Victoria Alcazar
Journal:  Int Wound J       Date:  2017-07-23       Impact factor: 3.315

2.  Palliative analgesia with topical sevoflurane in cancer-related skin ulcers: a case report.

Authors:  F Dámaso Fernández-Ginés; Manuel Cortiñas-Sáenz; Ana Navajas-Gómez de Aranda; Maria Del Carmen Navas-Martinez; José Antonio Morales-Molina; Francisco Sierra-García; Héctor Mateo-Carrasco
Journal:  Eur J Hosp Pharm       Date:  2018-01-11

Review 3.  Inhaled Sedation for Invasively Ventilated COVID-19 Patients: A Systematic Review.

Authors:  Giovanni Landoni; Olivia Belloni; Giada Russo; Alessandra Bonaccorso; Gianmarco Carà; Matthieu Jabaudon
Journal:  J Clin Med       Date:  2022-04-29       Impact factor: 4.964

4.  Effects of Sevoflurane Inhalation Anesthesia on the Intestinal Microbiome in Mice.

Authors:  Ci Han; Zhaodi Zhang; Nana Guo; Xueting Li; Mengyuan Yang; Yahui Peng; Xiaohui Ma; Kaijiang Yu; Changsong Wang
Journal:  Front Cell Infect Microbiol       Date:  2021-03-18       Impact factor: 5.293

5.  Screening of antibacterial compounds with novel structure from the FDA approved drugs using machine learning methods.

Authors:  Wen-Xing Li; Xin Tong; Peng-Peng Yang; Yang Zheng; Ji-Hao Liang; Gong-Hua Li; Dahai Liu; Dao-Gang Guan; Shao-Xing Dai
Journal:  Aging (Albany NY)       Date:  2022-02-12       Impact factor: 5.682

6.  Mucosal immune cell populations and the bacteriome of adenoids and tonsils from people living with HIV on suppressive antiretroviral therapy.

Authors:  Olivia Briceño; Mauricio Gónzalez-Navarro; Nadia Montufar; Monserrat Chávez-Torres; Indira Abato; Ariana Espinosa-Sosa; Yuria Ablanedo-Terrazas; Yara Luna-Villalobos; Santiago Ávila-Ríos; Gustavo Reyes-Terán; Sandra Pinto-Cardoso
Journal:  Front Microbiol       Date:  2022-08-11       Impact factor: 6.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.